During the last session, Health Catalyst Inc (NASDAQ:HCAT)’s traded shares were 0.88 million, with the beta value of the company hitting 1.45. At the end of the trading day, the stock’s price was $4.55, reflecting an intraday loss of -1.09% or -$0.05. The 52-week high for the HCAT share is $9.24, that puts it down -103.08 from that peak though still a striking 17.36% gain since the share price plummeted to a 52-week low of $3.76. The company’s market capitalization is $319.46M, and the average intraday trading volume over the past 10 days was 0.69 million shares, and the average trade volume was 829.38K shares over the past three months.
Health Catalyst Inc (HCAT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.46. HCAT has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.0.
Health Catalyst Inc (NASDAQ:HCAT) trade information
Health Catalyst Inc (HCAT) registered a -1.09% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.09% in intraday trading to $4.55, hitting a weekly high. The stock’s 5-day price performance is 3.17%, and it has moved by 3.64% in 30 days. Based on these gigs, the overall price performance for the year is -39.25%. The short interest in Health Catalyst Inc (NASDAQ:HCAT) is 2.94 million shares and it means that shorts have 2.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 24.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $7 respectively. As a result, HCAT is trading at a discount of -53.85% off the target high and -9.89% off the low.
Health Catalyst Inc (HCAT) estimates and forecasts
In the rating firms’ projections, revenue will increase 9.12% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 79.13M as predicted by 14 analyst(s). Meanwhile, a consensus of 14 analyst(s) estimates revenue growth to 82.88M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 74.72M and 75.9M respectively. In this case, analysts expect current quarter sales to grow by 5.90% and then jump by 9.20% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.24%. While earnings are projected to return 5.23% in 2025, the next five years will return 37.30% per annum.
HCAT Dividends
Health Catalyst Inc is due to release its next quarterly earnings on 2025-Feb-25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Health Catalyst Inc (NASDAQ:HCAT)’s Major holders
Health Catalyst Inc insiders own 3.50% of total outstanding shares while institutional holders control 76.54%, with the float percentage being 79.31%. BLACKROCK INC. is the largest shareholder of the company, while 226.0 institutions own stock in it. As of 2024-06-30, the company held over 5.43 million shares (or 9.1608% of all shares), a total value of $34.72 million in shares.
The next largest institutional holding, with 4.53 million shares, is of VANGUARD GROUP INC’s that is approximately 7.7263% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $28.93 million.
Also, the Mutual Funds coming in first place with the largest holdings of Health Catalyst Inc (HCAT) shares are IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund owns about 2.75 shares. This amounts to just over 3.92 percent of the company’s overall shares, with a $12.51 million market value. The same data shows that the other fund manager holds slightly less at 1.81, or about 2.58% of the stock, which is worth about $8.23 million.
